Evidence map›Paper›PMID 33101558›Full record

ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2020

Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients.

Adam Kaplan, Jo-Anne H Young, Raja Kandaswamy, Danielle Berglund, Bettina M Knoll, Gretchen Sieger, Winston Cavert, Arthur Matas, Karam M Obeid

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Daily Fungal Cell-Free DNA Testing to Assess Clinical Status duringJournal of fungi (Basel, Switzerland) · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Adam KaplanUniversity of Minnesota, School of Public Health, Division of Biostatistics, Minneapolis, Minnesota 5455, USA.
Jo-Anne H YoungUniversity of Minnesota, Department of Medicine, Division of Infectious Diseases and International Medicine, Minneapolis, Minnesota 55455, USA.
Raja KandaswamyUniversity of Minnesota, Department of Surgery, Minneapolis, Minnesota 55455, USA.
Danielle BerglundUniversity of Minnesota, Clinical and Translational Science Institute, Minneapolis, Minnesota 55455, USA.
Bettina M KnollNew York Medical College, Department of Medicine, Valhalla, New York 10595, USA.
Gretchen SiegerUniversity of Minnesota, Clinical and Translational Science Institute, Minneapolis, Minnesota 55455, USA.
Winston CavertUniversity of Minnesota, Department of Medicine, Division of Infectious Diseases and International Medicine, Minneapolis, Minnesota 55455, USA.
Arthur MatasUniversity of Minnesota, Department of Surgery, Minneapolis, Minnesota 55455, USA.
Karam M ObeidUniversity of Minnesota, Department of Medicine, Division of Infectious Diseases and International Medicine, Minneapolis, Minnesota 55455, USA.ORCID https://orcid.org/0000-0002-4131-647X
University of Minnesota · USNew York Medical College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple doses of alemtuzumab for immunosuppressive therapy of patients with hematologic malignancies and hematopoietic stem cell transplant have been associated with a high rate of infection. In transplantation, limited alemtuzumab dosing has been successfully used as induction immunosuppression. The effect of multiple doses of alemtuzumab, used as maintenance therapy to minimize steroid and/or calcineurin inhibitor toxicity in solid organ transplant recipients, is unknown. We evaluated the infectious and noninfectious outcomes of 179 pancreas transplant recipients treated with alemtuzumab for induction and maintenance therapy (extended alemtuzumab exposure (EAE)) from 2/28/2003 through 8/31/2005, compared with 159 pancreas transplant recipients with standard induction and maintenance (SIM) therapy performed before (1/1/2002 until 12/31/2002) and after (1/1/2006 until 12/31/2006) the implementation of EAE. EAE was associated with higher risk of overall infections (hazard ratio (HR) 1.33 (1.06-1.66),

Identifiers

PMID33101558
PMCPMC7569440
OpenAlexW3092390595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.